Paroxetine as First‑Line Pharmacotherapy for Premature Ejaculation

Efficacy of Paroxetine

Paroxetine (10–40 mg daily) provides the greatest ejaculation delay among all selective serotonin reuptake inhibitors, increasing intravaginal ejaculatory latency time (IELT) by an average 8.8‑fold over baseline, as demonstrated in a meta‑analysis of adult men with premature ejaculation【1】【2】【3】.
Daily paroxetine (10–40 mg) yields a superior ejaculatory delay compared with on‑demand dosing, confirming its advantage as a continuous therapy【1】【2】.
The European Association of Urology (2025) and the American Urological Association/Society of Male Sexual and Reproductive Health (2022) issue strong recommendations for SSRIs—including paroxetine—as first‑line pharmacologic treatment of premature ejaculation【5】【1】【2】【3】.

Initiate paroxetine at 10–20 mg once daily and titrate up to 40 mg daily based on symptom response and tolerability【1】【2】【3】.
Titration to the maximum dose is typically performed after 2–4 weeks of therapy if the desired IELT improvement has not been achieved【1】【2】【3】.

Administer 20 mg of paroxetine 3–6 hours before intercourse for patients who cannot adhere to daily therapy【1】【2】【4】.
On‑demand dosing produces a modest ejaculatory delay that is significantly less than that achieved with daily dosing【1】【2】【4】.
On‑demand use may be combined with an initial trial of daily therapy or with concomitant low‑dose daily paroxetine to enhance efficacy【1】【2】.

Serotonin syndrome is a serious risk when paroxetine is combined with other serotonergic agents (e.g., other SSRIs, tricyclic antidepressants, amphetamines, cocaine). Early signs include clonus, tremor, hyperreflexia, agitation, diaphoresis, fever, and in severe cases seizures or rhabdomyolysis【1】【2】【4】. Immediate discontinuation of serotonergic drugs and administration of benzodiazepines are recommended for management【1】【2】【4】.
Avoid paroxetine in men with bipolar depression because of the risk of inducing mania【1】【2】【4】.
Exercise caution in adolescents with premature ejaculation and in men with comorbid depressive disorders, especially when suicidal ideation is present; however, increased suicidal risk has not been observed in non‑depressed men with premature ejaculation【1】【2】【3】【6】.
Abrupt discontinuation or rapid dose reduction should be avoided to prevent SSRI withdrawal syndrome【1】【2】【4】.
Common dose‑dependent adverse effects (similar to dapoxetine) include nausea, diarrhea, dizziness, fatigue, yawning, and abnormal sleep patterns【5】.

Paroxetine is off‑label for premature ejaculation; it is not FDA‑approved for this indication, although it is approved for major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD【1】【2】.

Approximately 40 % of men either refuse to start or discontinue paroxetine within the first 12 months, primarily due to concerns about taking an antidepressant, perceived insufficient therapeutic effect, and medication cost【1】【2】【3】.

Adding a phosphodiesterase‑5 inhibitor (e.g., tadalafil) or behavioral therapy to paroxetine improves outcomes compared with paroxetine monotherapy, as endorsed by the European Association of Urology (2025)【5】.